Feinstein Institutes Awarded $3.6M From New York State For Spinal Cord Injury Research In order to govern our motions and process sensations, the spinal cord functions as the information highway, conveying impulses to and from our brain. A spinal cord injury (SCI) can cause paralysis, sometimes affecting all four limbs. […]
Featured News
FDA Approves First Gene Therapy to Treat Adults with Hemophilia B
Hemgenix (etranacogene dezaparvovec), an adeno-associated virus vector-based gene therapy, has been approved by the U.S. Food and Drug Administration for the treatment of adults with Haemophilia B (congenital factor IX deficiency) who are currently receiving Factor IX prophylaxis therapy, have experienced recent or past life-threatening hemorrhage, or have had recurrent, […]
Blue Cross Blue Shield Of Massachusetts Supports Vaccination To Help Prevent The Spread Of Flu
With the holiday season approaching and the AAA forecasting more holiday travel, Blue Cross and Blue Shield of Massachusetts, Inc. (Blue Cross) are encouraging everyone to get the flu vaccine and COVID-19 booster shot. I am urging you. “The best way to protect yourself and your loved ones is to […]
Jazz Pharmaceuticals Announces U.S. FDA Approval of Monday/Wednesday/Friday Intramuscular Dosing Schedule for Rylaze®
Jazz Pharmaceuticals Announces U.S. FDA Approval For Intramuscular Dosing Schedule for Rylaze Rylaze dosing option provides sustained asparaginase activity throughout the course of treatment for adult and pediatric patients with acute lymphoblastic leukemia or lymphoblastic lymphoma Jazz Pharmaceuticals plc announced today that in the United States the Food and Drug […]
Medidata Launches Rave Companion, the First Scalable Solution to Automate EHR Data Entry in Rave EDC
For clinical trial sites and data administrators, Rave Companion modernises the CDE user experience and prevents thousands of avoidable errors. Because Rave Companion enters EHR source data into Rave EDC with less typing and fewer errors, it improves data quality and can save monitoring expenses. The solution brings a patient’s […]
Google Cloud Launches New ‘Accelerators’ to Help Healthcare Companies Improve Health Equity, Patient Flow, and Value-Based Care
Collaboration with organisations like Lifepoint Health, Hackensack Meridian Health, and others will help businesses operate more successfully and provide better patient care. Today at HLTH 2022, Google Cloud unveiled three new Healthcare Data Engine (HDE) accelerators that support organisations in addressing common use cases related to health equity, patient flow, […]
Indivior To Acquire Opiant Pharmaceuticals
According to a definitive agreement between Indivior PLC and Opiant Pharmaceuticals, Inc., which the two companies announced today, Indivior will buy Opiant for an upfront payment of $20.00 per share in cash (roughly $145 million total), plus up to $8.00 per share in contingent value rights (“CVRs”) that could become […]
Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company
Creating a New Paradigm in Precision Medicine for The Company Fulgent Pharma Holdings, Inc., an independent clinical-stage, therapeutics development company focused on the development of cutting-edge cancer treatments, has been acquired by Fulgent Genetics, Inc., a technology-based genetic testing business focused on transforming patient care in oncology, infectious and rare […]
Karyopharm and Menarini Group announce orphan drug designation by the European Commission for selinexor for the treatment of myelofibrosis
The Menarini Group, a prominent privately held international pharmaceutical company, and Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Commission (EC) has granted selinexor orphan Medicinal Product Designation. It is intended to be used to treat myelofibrosis (MF). In May 2022, the […]
CSL Enters Licensing Agreement with Arcturus Therapeutics for Next Generation mRNA Vaccine Technology
CSL Enters Licensing Agreement with Arcturus Therapeutics : Today, CSL Limited reports that its subsidiary, CSL Seqirus, has collaborated and licenced its late-stage self-amplifying mRNA (sa-mRNA) vaccine platform technology to Arcturus Therapeutics Holdings Inc (or “Arcturus Therapeutics”). Future mRNA vaccines are being created by Arcturus Therapeutics. It has created a […]
